Date Document
20/12/2016 Zelda to Test Formulations Against Pancreatic Cancer
16/12/2016 Company Secretary Appointment
12/12/2016 Sleep Disorder Clinical Trials Update
05/12/2016 Collaboration Agreement with Telethon Kids Institute
30/11/2016 Significant Anti-Cancer Effect Observed in Studies
28/11/2016 Results of Meeting
25/11/2016 Becoming a substantial holder
25/11/2016 Change in substantial holding
25/11/2016 Change in substantial holding
25/11/2016 Zelda expands its Intellectual Property portfolio
23/11/2016 Becoming a substantial holder
23/11/2016 OpenBriefing Recording with Dr Stewart Washer
22/11/2016 Investor Presentation
22/11/2016 Zelda Therapeutics Debuts on ASX
18/11/2016 Zelda Therapeutics Pty Ltd - 30 June 2016 Accounts
18/11/2016 Zelda Therapeutics Pty Ltd - 31 December 2015 Accounts
18/11/2016 Updated Pro-Forma Statement
18/11/2016 Updated Statement of Commitments
18/11/2016 Confirmations
18/11/2016 Securities trading policy
18/11/2016 Top 20 holders
18/11/2016 Capital Structure and Restricted Securities
18/11/2016 Constitution
18/11/2016 Distribution schedule
18/11/2016 Appendix 1A and Information Form and Checklist
18/11/2016 Pre-reinstatement disclosure
18/11/2016 Reinstatement to Official Quotation - 22 November 2016
18/11/2016 ASX Notice - Reinstatement to Official Quotation
17/11/2016 Initial Director's Interest Notice x 4
17/11/2016 Final Director's Interest Notice x 3
17/11/2016 Appendix 3B
15/11/2016 Successful $4m Capital Raising
08/11/2016 Supplementary Prospectus
31/10/2016 Quarterly Activities Report
31/10/2016 Quarterly Cashflow Report
28/10/2016 Notice of Annual General Meeting/Proxy Form
26/10/2016 ASX Waiver Granted
12/10/2016 Consolidation Complete
12/10/2016 Supplementary Prospectus